Amersham International subsidiary Medi-Physics of Arlington Heights,IL, has received an approvable letter from the Food and Drug Administrationfor Myoview, its technetium-based cardiac imaging agent. Myoviewwill complement Amersham's thallium-201-based
Amersham International subsidiary Medi-Physics of Arlington Heights,IL, has received an approvable letter from the Food and Drug Administrationfor Myoview, its technetium-based cardiac imaging agent. Myoviewwill complement Amersham's thallium-201-based imaging productand will compete with Du Pont Merck's Cardiolite agent. Medi-Physicswill emphasize the fast clearance of Myoview as well as the product'sease of use compared to thallium agents. Final FDA approval isexpected within a few months, according to the company.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.